SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Niroula Abhishek)
 

Search: WFRF:(Niroula Abhishek) > (2021) > Distinction of lymp...

  • Niroula, AbhishekLund University,Lunds universitet,Hematogenomics,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Broad Institute,Dana-Farber Cancer Institute (author)

Distinction of lymphoid and myeloid clonal hematopoiesis

  • Article/chapterEnglish2021

Publisher, publication year, extent ...

  • 2021-10-18
  • Springer Science and Business Media LLC,2021

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:79ebc715-db23-4446-95e7-3604661df0db
  • https://lup.lub.lu.se/record/79ebc715-db23-4446-95e7-3604661df0dbURI
  • https://doi.org/10.1038/s41591-021-01521-4DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Clonal hematopoiesis (CH) results from somatic genomic alterations that drive clonal expansion of blood cells. Somatic gene mutations associated with hematologic malignancies detected in hematopoietic cells of healthy individuals, referred to as CH of indeterminate potential (CHIP), have been associated with myeloid malignancies, while mosaic chromosomal alterations (mCAs) have been associated with lymphoid malignancies. Here, we analyzed CHIP in 55,383 individuals and autosomal mCAs in 420,969 individuals with no history of hematologic malignancies in the UK Biobank and Mass General Brigham Biobank. We distinguished myeloid and lymphoid somatic gene mutations, as well as myeloid and lymphoid mCAs, and found both to be associated with risk of lineage-specific hematologic malignancies. Further, we performed an integrated analysis of somatic alterations with peripheral blood count parameters to stratify the risk of incident myeloid and lymphoid malignancies. These genetic alterations can be readily detected in clinical sequencing panels and used with blood count parameters to identify individuals at high risk of developing hematologic malignancies.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Sekar, AswinDana-Farber Cancer Institute (author)
  • Murakami, Mark A.Dana-Farber Cancer Institute (author)
  • Trinder, MarkBroad Institute,University of British Columbia (author)
  • Agrawal, MridulDana-Farber Cancer Institute (author)
  • Wong, Waihay J.Broad Institute (author)
  • Bick, Alexander G.Vanderbilt University,Broad Institute (author)
  • Uddin, Md MesbahBroad Institute,Massachusetts General Hospital (author)
  • Gibson, Christopher J.Broad Institute,Dana-Farber Cancer Institute (author)
  • Griffin, Gabriel K.Broad Institute (author)
  • Honigberg, Michael C.Broad Institute,Massachusetts General Hospital (author)
  • Zekavat, Seyedeh M.Broad Institute,Yale University (author)
  • Paruchuri, KaavyaBroad Institute,Harvard Medical School,Massachusetts General Hospital (author)
  • Natarajan, PradeepHarvard Medical School,Massachusetts General Hospital,Broad Institute (author)
  • Ebert, Benjamin L.Dana-Farber Cancer Institute,Howard Hughes Medical Institute,Broad Institute (author)
  • HematogenomicsForskargrupper vid Lunds universitet (creator_code:org_t)

Related titles

  • In:Nature Medicine: Springer Science and Business Media LLC27:11, s. 1921-19271078-89561546-170X

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view